Insect Cell Culture Seed Expansion Patents: Leaders & White Space 2026
Insect Cell Culture Seed Expansion Patents: Who Holds the Seed Train Claims
Concentrated but not locked up. the top 5 of 98 ranked assignees hold 33.0% of all 224 records in scope, and the top 10 hold 54.9% — leaving a long tail of single- and few-filing entrants. Filings moved from 6 records in 2021 to a peak of 10 in 2024, a 67% rise over three years. 2025 and 2026 figures will continue to fill in as later-filed applications publish, so treat the tail of the chart as incomplete rather than declining.
- 1BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH INC18
- 2THE SCRIPPS RES INST17
- 3ZOETIS SERVICES LLC14
- 4QHSLAB INC13
- 5GLYCOBAC LLC12
See the full insect cell culture seed expansion analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who holds the most patents in insect cell culture seed expansion?
The dataset ranks 98 companies by record count, with the leading assignee holding 18 of the 224 records in scope. The top 5 assignees together account for 33.0% of all records, and the top 10 account for 54.9%, which means concentration is real at the very top but drops off quickly — by the tenth-ranked assignee the count is down to 7 records. This is not a field with a single dominant gatekeeper; it has a strong leader and a wide field of smaller filers behind it.
Is filing activity in this field growing or slowing down?
Filing activity grew from 6 records in 2021 to 10 in 2024, a 67% increase over that three-year span, and 2024 is the most recent year that can be read as complete. Publication typically lags actual filing by around 18 months, so the apparent drop in 2025 and 2026 numbers reflects records still working through publication, not a real slowdown. Based on the complete years, the trend points upward rather than flat or declining.
What does US9611455B2 actually cover?
US9611455B2, assigned to Merck Sharp & Dohme LLC and published in 2017, covers raising culture pH above standard conditions during baculovirus infection of lepidopteran insect cells, plus insect cell lines derived from lines such as Sf21 that are adapted to grow well at that elevated pH. It is specifically tied to producing pH-sensitive recombinant proteins, including chikungunya virus-like particles, in the correct conformation. Anyone working on elevated-pH culture conditions or pH-adapted cell line derivatives for recombinant VLP production should check their process parameters against this claim scope directly.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Insect Cell Culture Seed Expansion covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.